XOMA Royalty Corporation
$40.17$0.00 (0.0%)
Last close · Data as of Jul 21, 2026
- Market cap
- $531.7M
- P/E
- 16.8x
- EV / EBITDA
- 12.1x
- Revenue
- $11.7M
- Net margin
- 272.0%
- ROCE
- 4.8%
Price chart
Technical chartScreen technicals →Hidden because the last close is more than three trading days older than the latest prices of its class.
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 21 Jul 2026 close.
- 1M
- Stale
- 3M
- Stale
- 6M
- Stale
- 1Y
- Stale
- 5Y
- Stale
- Hidden because the last close is more than three trading days older than the latest prices of its class.
52-week range
Day change $0.00 (0.0%) from $40 to $40 · Last close Jul 21, 2026
Best weekday to invest, historically
The same weekly amount in XOMA, bought on each weekday since 2021.
News & filings
What XOMA Royalty filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthReturn on equity of 37.8%.
Concerns (1)
- Operating cash flow was 0.09 times net profit in fiscal 2025.
- Prices are as of 21 Jul 2026; price-based points are paused until newer prices arrive.
Prices to the 21 Jul 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates.
Read moreShow less
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
- Sector
- Healthcare
- Shares outstanding
- 20.7M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $531.7M
- P/E
- 16.8x
- P/B
- 6.3x
- EV / EBITDA
- 12.1x
- EV / Sales
- 49.8x
- P/S
- 45.6x
- 52-week high
- $45.00
- 52-week low
- $22.89
Profitability
- Operating margin
- 97.6%
- Net margin
- 272.0%
- EBITDA margin
- 410.1%
- ROE
- 37.8%
- ROCE
- 4.8%
- ROIC
- 33.7%
- ROA
- 11.6%
- Asset turnover
- 0.04
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $11.7M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 14.1%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 24.6%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -329.4%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$17.9M
Solvency
- Current ratio
- 3.37
- Debt / Equity
- 1.57
- Debt / Assets
- 0.48
- CFO / Net profit
- 0.09
- Cash / Market cap
- 15.6%
Where the revenue went
Of every $100 of FY2025 revenue, $272 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Gross profit | $11.7M |
| Gross profit | Operating expenses | $280.0k |
| Gross profit | Operating income | $11.4M |
| Operating income | Pretax income | $11.4M |
| Interest and other income | Pretax income | $20.4M |
| Pretax income | Tax and other | $110.0k |
| Pretax income | Net income | $31.7M |
Revenue and net profit
Revenue grew 14.1% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $6.0M | -$17.1M |
| FY2023 | $4.8M | -$40.8M |
| FY2024 | $10.2M | -$13.8M |
| FY2025 | $11.7M | $31.7M |
Cash flows
FY2025: $2.9M from operations, -$17.9M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$12.9M | -$28.1M |
| FY2023 | -$18.2M | -$18.2M |
| FY2024 | -$13.7M | -$13.8M |
| FY2025 | $2.9M | -$17.9M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $11.7M+14.1%1Y
- EBITDA
- $47.8M
- Net profit
- $31.7M
- Cash from operations
- $2.9M
- Free cash flow
- -$17.9M
- Revenue CAGR, 3Y
- 24.6%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $11.7M | $47.8M | $31.7M | -$17.9M | 37.8% | +14.1% | -329.4% |
Monthly returns
Month-by-month returns of XOMA across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $272.7M |
| Current assets | $117.3M |
| Non-current assets | $155.4M |
| Liabilities | $188.8M |
| Current liabilities | $34.8M |
| Non-current liabilities | $153.9M |
| Equity | $83.9M |
| Paid-in capital | $1.3B |
| Retained earnings | -$1.2B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; XOMA highlighted.
P/E against peers
XOMA trades at 16.8x earnings against a peer median of -6.2x.
Not shown (no positive earnings and no EV / Sales): Tectonic Therapeutic, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| XOMA Royalty CorporationXOMAthis company | $531.7M | 16.8x | 6.3x | 37.8% | 12.1x |
| Cerus CorporationCERS | $559.0M | — | 8.7x | -24.3% | — |
| NeuroPace, Inc.NPCE | $556.4M | -25.9x | 29.2x | -112.8% | -50.2x |
| Fulgent Genetics, Inc.FLGT | $553.8M | -9.2x | 0.5x | -5.4% | -11.2x |
| Tectonic Therapeutic, Inc.TECX | $549.7M | -7.4x | 2.2x | -29.5% | -4.2x |
| Strata Critical Medical, Inc.SRTA | $541.7M | 13.1x | 1.9x | 14.8% | -36.3x |
| 4D Molecular Therapeutics, Inc.FDMT | $523.3M | -3.7x | 1.0x | -27.7% | -3.2x |
| Aquestive Therapeutics, Inc.AQST | $519.4M | -6.2x | -15.4x | 248.9% | -6.7x |
| Pacific Biosciences of California, Inc.PACB | $506.3M | -0.9x | 94.6x | -10214.5% | -7.5x |
| Peer median | — | -6.2x | 2.1x | -26.0% | -7.5x |
Year-to-date ROI
XOMA since 1 January, against earlier years.
Historical volatility
XOMA's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -288.7% |
| FY2023 | -492.9% |
| FY2024 | -391.2% |
| FY2025 | 97.6% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $11.7M |
| Operating expensesOperating Expense | $280.0k |
| Research and developmentResearch And Development | $1.7M |
| Selling, general and administrativeSelling General And Administration | $36.1M |
| Other operating expensesOther Operating Expenses | -$40.5M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $3.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $3.0M |
| Amortization | $3.0M |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $3.0M |
| Provision for doubtful accountsProvision For Doubtful Accounts | $0.00 |
| Total expensesTotal Expenses | $280.0k |
| Operating incomeOperating Income | $11.4M |
| Interest and other | |
| Pretax incomePretax Income | $31.8M |
| TaxTax Provision | $100.0k |
| Net incomeNet Income | $31.7M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $272.7M |
| Current assetsCurrent Assets | $117.3M |
| Non-current assetsTotal Non Current Assets | $155.4M |
| LiabilitiesTotal Liabilities Net Minority Interest | $188.8M |
| Current liabilitiesCurrent Liabilities | $34.8M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $153.9M |
| EquityTotal Equity Gross Minority Interest | $83.9M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $2.9M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $2.9M |
| Net income, continuing operationsNet Income From Continuing Operations | $31.7M |
| Depreciation and amortisationDepreciation And Amortization | $3.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $3.0M |
| Depreciation | $10.0k |
| Amortization cash flowAmortization Cash Flow | $3.0M |
| Amortization of intangiblesAmortization Of Intangibles | $3.0M |
| Stock-based compensationStock Based Compensation | $9.3M |
| Deferred taxDeferred Tax | $100.0k |
| Deferred income taxDeferred Income Tax | $100.0k |
| Operating gains and lossesOperating Gains Losses | -$3.6M |
| Gain loss on investment securitiesGain Loss On Investment Securities | -$3.8M |
| Gain loss on sale of businessGain Loss On Sale Of Business | — |
| Unrealized gain loss on investment securitiesUnrealized Gain Loss On Investment Securities | -$110.0k |
| Asset impairmentAsset Impairment Charge | — |
| Pension and employee benefit expensePension And Employee Benefit Expense | $140.0k |
| Change in working capitalChange In Working Capital | -$11.4M |
| Other non-cash itemsOther Non Cash Items | -$26.1M |
| Investing cash flowInvesting Cash Flow | $50.9M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $50.9M |
| Capital expenditureCapital Expenditure | -$20.7M |
| Purchase of PP&EPurchase Of PPE | $0.00 |
| Net PP&E purchases and salesNet PPE Purchase And Sale | $0.00 |
| AcquisitionsPurchase Of Business | $0.00 |
| DisposalsSale Of Business | $8.3M |
| Net acquisitions and disposalsNet Business Purchase And Sale | $8.3M |
| Purchase of investmentsPurchase Of Investment | -$100.0k |
| Sale of investmentsSale Of Investment | $7.0M |
| Net investment purchases and salesNet Investment Purchase And Sale | $6.9M |
| Purchase of intangiblesPurchase Of Intangibles | -$20.7M |
| Sale of intangiblesSale Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$20.7M |
| Other investing changesNet Other Investing Changes | $56.4M |
| Financing cash flowFinancing Cash Flow | -$26.5M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$26.5M |
| Debt issuedIssuance Of Debt | — |
| Debt repaidRepayment Of Debt | -$10.6M |
| Net debt issuedNet Issuance Payments Of Debt | -$10.6M |
| Long-term debt issuedLong Term Debt Issuance | — |
| Long-term debt repaidLong Term Debt Payments | -$10.6M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$10.6M |
| Shares issuedIssuance Of Capital Stock | $4.3M |
| Common stock issuedCommon Stock Issuance | $320.0k |
| Net common stock issuedNet Common Stock Issuance | -$15.7M |
| Common stock repurchasedCommon Stock Payments | -$16.0M |
| Share buybacksRepurchase Of Capital Stock | -$16.7M |
| Stock options exercisedProceeds From Stock Option Exercised | $5.0M |
| Preferred stock issuancePreferred Stock Issuance | $4.0M |
| Preferred stock paymentsPreferred Stock Payments | -$670.0k |
| Net preferred stock issuanceNet Preferred Stock Issuance | $3.4M |
| Dividends paidCash Dividends Paid | -$5.5M |
| Preferred stock dividend paidPreferred Stock Dividend Paid | -$5.5M |
| Other financing chargesNet Other Financing Charges | -$3.1M |
| Change in cashChanges In Cash | $27.3M |
| Cash at the start of the yearBeginning Cash Position | $106.4M |
| Cash at the end of the yearEnd Cash Position | $133.7M |
| Free cash flowFree Cash Flow | -$17.9M |
| Supplemental |
Learn while you research
Academy chapters picked for XOMA Royalty Corporation and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Leverage RatiosDebt/Equity of 1.57 is elevated, understand what that means for solvency.6 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read